ICYMI: Blockchain, Bitcoin, And Biotech

In case you missed it, here are some of Benzinga's top stories from Monday, Dec. 10, 2017.

Shorts Target Crypto

Todd Shriber’s "Shorts Take Aim At Bitcoin Investments" details the gutsy move some short sellers are making to bet against the mercurial digital currency in the wake of the launch of bitcoin futures.

Bluebird Bio Hatches Some Impressive Data At ASH 2017 Meeting

Bluebird Bio, Inc BLUE made quite an impression at this year’s ASH meeting. In “After Data Release, Cantor Fitzgerald Doubles Bluebird Bio Price Target,” Jayson Derrick describes how a bearish firm reiterates an Underweight rating even as it doubles its price target.

Related Link: ICYMI: Digital Ad Spending On The Rise, Benzinga's Best From Last Week, And Barron's Best Bets For Next Year

Blockchain News Sends Riot Shares Higher

Riot Blockchain, Inc RIOT announced a subsidiary’s merger, and shares took off as much as 40 percent. Elizabeth Balboa explains.

MoviePass Makes A Deal

Looking to understand the move in Helios And Matheson Analytics Inc HMNY shares Monday? Check out Balboa’s "MoviePass Expands Revenue Source With Distributor Deal." Helios and Matheson has made a big bet on MoviePass, and Monday’s news of a revenue-sharing deal with a film distributor may be proof it’s paying off.

Market News and Data brought to you by Benzinga APIs
Posted In: NewsMediaReviewsBZ ICYMI
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...